Vertex presents positive vx-880 results from ongoing phase 1/2 study in type 1 diabetes at the american diabetes association 83rd scientific sessions

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today presented data on all patients dosed in parts a and b of its phase 1/2 clinical trial of vx-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (t1d) with impaired hypoglycemic awareness and severe hypoglycemic events (shes). all six patients treated with vx-880 had undetectable fasting c-peptide (endogenous insulin secretion) at baseline, a history of.
VRTX Ratings Summary
VRTX Quant Ranking